In AF and stable CAD, rivaroxaban reduced cardiovascular events and mortality more than rivaroxaban plus an antiplatelet. Santulli G. Ann Intern Med 2020;172:JC6.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Santulli G. In AF and stable CAD, rivaroxaban reduced cardiovascular events and mortality more than rivaroxaban plus an antiplatelet. Ann Intern Med 2020;172:JC6.
PMID: 31958820